Agilent Technologies, expanding on the company’s precision oncology testing, is acquiring Resolution Bioscience.
Caris Life Sciences secured $310 million in growth capital that will be used to expand the molecular science company’s presence in precision medicine in oncology.
This webinar will discuss a set of in vitro assays that tackle the challenges of in vitro hepatotoxicity assessment.
The U.S. Food and Drug Administration granted Ortho Clinical Diagnostics’ total antibody assay for COVID-19 Emergency Use Authorization.
Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).
Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, and KingMed Diagnostics, a laboratory services leader in China, announced that they have entered into a strategic partnership for the PGDx elioTM tissue complete assay.
Reaction Biology Corporation, a leading contract research organization providing early-stage drug discovery services, announced that it has launched a new division to provide ion-channel discovery services.